Cancer Family
Immunodeficiency-Related Malignant Neoplasm
CI-CAN-00000204Explore in graph →
15 active trials3 approved drugs
- NCIt
- C27770
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000204Explore in graph →
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02619682 | Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT00006436 | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04975698 | HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903(BMTCTN1903) | completed | Phase 2 | 12 | Catherine BollardNIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | not yet recruiting | Phase 2 | 146 | Center for International Blood and Marrow Transplant ResearchNETWORK | 0 | Jun 22, 2026 | clinicaltrials |
| NCT04929028 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT04237623 | GM-CSF With Post-Transplant Cyclophosphamide | recruiting | Phase 2 | 38 | Northside Hospital, Inc.OTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03961919 | Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant(FLAT-Auto) | completed | Phase 2 | 15 | Ciceri FabioOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT01775475 | Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma | completed | Phase 2 | 7 | AIDS Malignancy ConsortiumNETWORK | 2 | Oct 10, 2022 | clinicaltrials |
| NCT00858793 | High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT | terminated | Phase 1 / Phase 2 | 5 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT03434704 | Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole(SIR-POSA) | completed | Phase 2 | 10 | Ciceri FabioOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00001563 | EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2022 | clinicaltrials |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2020 | clinicaltrials |
| NCT01076543 | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2019 | clinicaltrials |
| NCT01282216 | Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide | terminated | Phase 2 | 120 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT01752569 | A Study of Selumetinib in Patients With Kaposi's Sarcoma(SCART) | terminated | Phase 1 / Phase 2 | 19 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00020683 | A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01045889 | High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk(HDT-HIV) | completed | Phase 2 | 27 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Feb 3, 2016 | clinicaltrials |
| NCT02137564 | Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Jul 23, 2015 | clinicaltrials |
| NCT00834457 | A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe | completed | Phase 2 / Phase 3 | 49 | Parirenyatwa HospitalOTHER | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00049036 | Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00521092 | Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 5, 2014 | clinicaltrials |
| NCT00799136 | A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL(CATCH) | completed | Phase 2 | 6 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 12, 2013 | clinicaltrials |
| NCT00064142 | Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00126243 | Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma | terminated | Phase 2 | 60 | French National Agency for Research on AIDS and Viral HepatitisOTHER_GOV | 1 | Aug 17, 2005 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials